
1. tanzan j health res. 2011 jan;13(1):40-7.

detecting adenosine triphosphatase 6 (pfatp6) point mutations may be
associated plasmodium falciparum resistance artemisinin: prevalence at
baseline, policy change uganda.

kamugisha e(1), sendagire h(2), kaddumukasa m(3), enweji n(4), gheysari f(4),
swedberg g(4), kironde f(2).

author information: 
(1)department biochemistry, bugando university college health sciences,
mwanza, tanzania. erasmuskamugisha@yahoo.com
(2)department microbiology, makerere university-kampala, uganda.
(3)department medicine, makerere university, kampala, uganda.
(4)department medical biochemistry microbiology, uppsala university,
sweden.

the artemisinin based combination therapy (act) artemether lumefantrine
(co-artem) recently replaced chloroquine fansidar first line
treatment policy drug uganda. necessary develop practical procedures 
to monitor likely emergence spread artemisinin resistant p. falciparum
strains. analyzed genotypes pfatp6 parasites 300 stored
filter paper samples malaria patients diagnosed treated 
years 1999 2004 three field sites uganda. period prior to
introduction co-artem. order develop simple molecular procedure for
mutation detection, regions pfatp6 encoding protein domains important in
artemisinin binding amplified nested pcr. three dna products, which
together contain coding region amino acids located within the
putative active site pfatp6 readily amplified. amplified dna was
digested restriction enzymes fragments sized agarose gel
electrophoresis. important codons 260, 263 769, methods using
engineered restriction sites employed. find mutations codons
for key residues lys 260, leu263, gln266, ser769 asn1039. nucleotide
sequencing pfatpase6 gene dna least 15 clinical isolates confirmed the
above findings suggested mutations amino acid residues not
emerged study sites.

doi: 10.4314/thrb.v13i1.58580 
pmid: 24409646  [indexed medline]

